Psoriasis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (TNF Inhibitors, Phosphodiesterase Inhibitors, Interleukin Blockers, Others), By Application (Oral, Injectable), Regional Insights and Forecast to 2035

Unique Information about the Psoriasis Treatment Market

Psoriasis Treatment Market size in 2026 is estimated to be USD 31831.81 million, with projections to grow to USD 56722.16 million by 2035 at a CAGR of 6.63%.

The Psoriasis Treatment Market is expanding due to the increasing burden of chronic inflammatory skin disorders affecting nearly 125 million people globally, representing around 2% to 3% of the world population. More than 30% of psoriasis patients develop psoriatic arthritis, increasing demand for biologics, oral therapies, and injectable drugs. Biologic therapies currently account for over 45% of prescription-based psoriasis treatment usage in severe cases, while topical therapies remain dominant among mild-to-moderate patients with nearly 60% treatment preference. Interleukin inhibitors, including IL-17 and IL-23 agents, demonstrated PASI 90 response rates above 70% in multiple clinical studies during 2024 and 2025. Hospital pharmacies contribute nearly 48% of prescription distribution for advanced psoriasis treatment products worldwide.

The United States accounts for approximately 32% of the global Psoriasis Treatment Market share due to the presence of over 7.5 million diagnosed psoriasis patients. Around 80% of U.S. psoriasis patients suffer from plaque psoriasis, while nearly 20% experience moderate-to-severe symptoms requiring systemic therapy or biologics. More than 40 FDA-approved psoriasis therapies are commercially available across oral, injectable, and topical categories. Injectable biologics represent nearly 58% of advanced psoriasis prescriptions in the country. Over 55% of dermatology clinics in the United States integrated biologic therapy monitoring systems by 2025. Psoriasis prevalence in adults remains close to 3.2%, while pediatric psoriasis contributes nearly 1% of diagnosed skin disease cases across the country.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Increasing biologic therapy adoption contributed to more than 48% treatment preference among moderate-to-severe psoriasis patients, while nearly 62% of dermatologists reported higher prescription rates for IL-17 and IL-23 inhibitors because of PASI 90 clearance outcomes exceeding 70% across long-term treatment cycles.
• Major Market Restraint: Nearly 41% of psoriasis patients discontinued biologic therapies due to treatment affordability concerns, while approximately 29% experienced therapy interruption linked with insurance restrictions, limited reimbursement access, and higher monitoring requirements for systemic psoriasis treatment medications.
• Emerging Trends: More than 54% of ongoing psoriasis clinical trials during 2025 focused on IL-23 inhibitors, TYK2 inhibitors, and biosimilars, while over 46% of dermatology centers integrated personalized biologic selection strategies based on inflammatory biomarkers and patient comorbidity profiles.
• Regional Leadership: North America maintained approximately 39% share of the Psoriasis Treatment Market due to high biologic adoption rates, while Europe contributed nearly 28% and Asia-Pacific accounted for almost 24% because of rising healthcare access and increasing psoriasis diagnosis rates.
• Competitive Landscape: Around 63% of the global psoriasis biologics segment remained concentrated among six multinational pharmaceutical companies, while nearly 52% of recently approved therapies targeted IL-17 and IL-23 inflammatory pathways for moderate-to-severe plaque psoriasis management.
• Market Segmentation: Injectable therapies accounted for approximately 57% of advanced psoriasis treatment demand, while oral therapies represented nearly 31% due to increasing preference for convenient administration and long-term compliance among patients with chronic plaque psoriasis.
• Recent Development: During 2024 and 2025, more than 18 late-stage psoriasis clinical trials evaluated next-generation biologics and TYK2 inhibitors, while nearly 44% of pipeline products focused on improving PASI 100 response rates and reducing treatment discontinuation.

Psoriasis Treatment Market Latest Trends

The Psoriasis Treatment Market is witnessing rapid transformation through the expansion of biologic therapies, biosimilars, and precision medicine approaches. IL-17 inhibitors demonstrated PASI 75 response rates above 78% within 12 weeks in several clinical evaluations conducted during 2025, while IL-23 inhibitors achieved long-term disease control rates exceeding 60% among moderate-to-severe psoriasis patients. More than 52% of newly launched psoriasis therapies between 2023 and 2025 targeted cytokine pathways such as IL-17, IL-23, and TNF-alpha. Oral TYK2 inhibitors gained attention as nearly 35% of dermatologists preferred oral systemic treatments for patients resistant to topical therapy.

Biosimilar penetration increased by approximately 28% in hospital procurement systems due to lower therapy costs and expanded reimbursement coverage. Digital dermatology consultations grew by nearly 40% globally, improving psoriasis diagnosis and treatment initiation rates in remote areas. Combination therapy adoption increased by more than 33% among severe psoriasis patients because biologics combined with methotrexate improved symptom reduction and reduced relapse frequency. Injectable therapies continued dominating advanced psoriasis treatment with approximately 57% market share, while oral therapies accounted for around 31%. Hospital pharmacies represented nearly 48% of treatment distribution channels because injectable biologics require clinical supervision and regular monitoring.

Psoriasis Treatment Market Dynamics

DRIVER

"Rising demand for biologic therapies and targeted immunology treatments"

The primary growth driver of the Psoriasis Treatment Market is the increasing use of biologic therapies for moderate-to-severe plaque psoriasis. More than 125 million individuals globally are affected by psoriasis, and nearly 30% of these patients develop psoriatic arthritis requiring advanced therapeutic intervention. IL-17 inhibitors achieved PASI 90 response rates above 70% in several studies conducted during 2024 and 2025, increasing physician preference for targeted therapies. Nearly 58% of advanced psoriasis prescriptions in developed economies involve injectable biologics because of superior long-term disease control compared to traditional systemic therapies. Around 46% of dermatologists reported increased patient demand for personalized biologic selection based on inflammatory biomarkers. In addition, over 55% of psoriasis clinical trials focused on cytokine-specific therapies, including IL-23 and TYK2 inhibitors, highlighting the strong innovation pipeline supporting Psoriasis Treatment Market growth.

RESTRAINT

"High treatment discontinuation and limited affordability in developing regions"

High treatment costs and reimbursement limitations continue restraining broader adoption of biologic therapies in the Psoriasis Treatment Market. Approximately 41% of patients discontinue advanced biologic therapies because of affordability concerns, while nearly 29% experience interruptions due to insurance authorization delays. Injectable biologics require regular monitoring, laboratory testing, and specialist consultations, increasing long-term treatment complexity. More than 38% of psoriasis patients in lower-income economies rely primarily on topical corticosteroids because biologic accessibility remains limited. Biosimilars improved affordability by nearly 22% in selected hospital procurement programs, but penetration remains uneven across developing healthcare systems. Nearly 33% of dermatology clinics in emerging economies still lack biologic administration infrastructure, slowing adoption rates for advanced injectable therapies. These barriers continue impacting long-term compliance and treatment continuity within the global Psoriasis Treatment Industry Analysis.

OPPORTUNITY

"Expansion of personalized medicine and oral TYK2 inhibitors"

The growing focus on personalized medicine creates substantial opportunities within the Psoriasis Treatment Market Forecast. More than 54% of ongoing psoriasis clinical trials are evaluating biomarker-based biologic selection and next-generation oral therapies. TYK2 inhibitors demonstrated symptom reduction rates above 60% in moderate plaque psoriasis cases during late-stage studies conducted in 2024 and 2025. Oral therapies currently account for approximately 31% of advanced psoriasis treatment demand, and adoption is increasing among patients preferring non-injectable options. Nearly 42% of healthcare providers reported higher patient adherence with oral immunomodulators compared to injectable therapies. Teledermatology adoption increased by over 40%, improving access to psoriasis diagnosis and treatment recommendations in underserved areas. Biosimilar expansion also creates opportunities, with hospital procurement of psoriasis biosimilars rising by approximately 28% during 2025 due to broader reimbursement support and increased physician confidence.

CHALLENGE

"Long-term safety monitoring and therapy switching"

Long-term safety concerns and therapy switching remain major challenges in the Psoriasis Treatment Market Outlook. Nearly 37% of biologic-treated patients required therapy modification within 24 months because of reduced efficacy, adverse reactions, or secondary treatment failure. TNF inhibitors demonstrated adverse event rates above 50% in selected severe psoriasis studies, while IL-17 inhibitors reported adverse event rates close to 46%. Around 34% of psoriasis patients undergoing systemic therapy require continuous laboratory monitoring for infection risks and immune complications. More than 27% of biologic-naive patients delayed treatment initiation due to concerns related to long-term immunosuppression. Switching between biologic classes increased by approximately 25% during 2025 because physicians sought improved PASI 100 outcomes and reduced relapse frequency. Regulatory approval timelines for advanced biologics also remain challenging, as over 18 pipeline therapies continued under multi-phase clinical evaluation during 2025.

Segmentation Analysis

The Psoriasis Treatment Market is segmented by type and application, with biologics dominating treatment demand among moderate-to-severe patients. Injectable biologics contribute approximately 57% of total advanced psoriasis treatment usage because of high PASI 90 response rates exceeding 70% in multiple studies. Oral therapies account for nearly 31% share due to rising patient preference for convenient administration and lower monitoring requirements. By type, TNF inhibitors hold approximately 42% share among biologics because of long-term clinical adoption and broad physician familiarity. Interleukin blockers contribute nearly 36% share due to improved disease clearance outcomes, while phosphodiesterase inhibitors represent close to 14% because of growing demand for oral systemic therapies in chronic plaque psoriasis management.

Download FREE Sample to learn more about this report.

By Type

TNF Inhibitors: TNF inhibitors account for approximately 42% of the biologic-focused Psoriasis Treatment Market due to extensive use in moderate-to-severe plaque psoriasis and psoriatic arthritis treatment. More than 45% of biologic-treated patients initiate therapy with TNF inhibitors because of long-established clinical safety profiles and physician confidence. PASI 75 response rates for TNF inhibitors remain above 50% in multiple clinical studies conducted during 2024 and 2025. Nearly 33% of psoriasis patients with joint complications continue receiving TNF inhibitor therapies because of combined anti-inflammatory effects on skin and musculoskeletal symptoms.

Phosphodiesterase Inhibitors: Phosphodiesterase inhibitors contribute approximately 14% share within the Psoriasis Treatment Market and continue gaining popularity because of oral administration convenience and lower biologic monitoring requirements. Nearly 42% of psoriasis patients preferring non-injectable systemic treatment selected phosphodiesterase inhibitors during 2025. More than 37% of mild-to-moderate plaque psoriasis patients demonstrated improved symptom management after initiating oral phosphodiesterase inhibitor therapy. Dermatologists reported approximately 31% higher treatment adherence among patients using oral therapies compared to injectable alternatives.

Interleukin Blockers: Interleukin blockers represent nearly 36% of the advanced Psoriasis Treatment Market due to superior clinical outcomes in severe plaque psoriasis management. IL-17 inhibitors achieved PASI 75 response rates exceeding 78% within 12 weeks in several studies conducted during 2025, while IL-23 inhibitors demonstrated long-term disease control rates above 60%. More than 54% of ongoing psoriasis clinical trials currently focus on IL-17 and IL-23 inflammatory pathways. Around 48% of patients treated with interleukin blockers achieved PASI 90 improvement after sustained therapy cycles. Injectable interleukin blockers dominate severe psoriasis treatment because of rapid symptom reduction and lower relapse frequency.

Others: The others category includes methotrexate, cyclosporine, topical corticosteroids, calcineurin inhibitors, vitamin D analogs, and emerging TYK2 inhibitors. This segment contributes approximately 8% of the advanced Psoriasis Treatment Market while remaining essential in mild-to-moderate disease management. More than 60% of psoriasis patients worldwide continue using topical therapies as first-line treatment options. Methotrexate remains prescribed for approximately 26% of systemic psoriasis cases because of broad clinical familiarity and affordability advantages. TYK2 inhibitors emerged as a significant innovation category during 2025, with symptom reduction rates above 60% in moderate plaque psoriasis studies.

By Application

Oral: Oral therapies account for approximately 31% of the Psoriasis Treatment Market because patients increasingly prefer convenient non-injectable treatment options. More than 42% of moderate psoriasis patients selected oral therapies over injectable biologics during 2025 due to ease of administration and lower clinical supervision requirements. Phosphodiesterase inhibitors and TYK2 inhibitors remain major contributors to oral therapy demand. Around 35% of dermatologists reported higher treatment adherence rates among oral therapy patients compared to injectable biologic users. Oral therapies are particularly significant in Asia-Pacific and developing healthcare systems where biologic infrastructure remains limited.

Injectable: Injectable therapies dominate the Psoriasis Treatment Market with approximately 57% share because biologic therapies remain the preferred option for moderate-to-severe plaque psoriasis. More than 58% of advanced psoriasis prescriptions in developed economies involve injectable biologics targeting IL-17, IL-23, and TNF-alpha pathways. PASI 90 response rates above 70% significantly increased physician confidence in injectable biologics during 2025. Around 44% of severe psoriasis patients receiving injectable therapies achieved substantial skin clearance within 16 weeks. Hospital pharmacies contribute nearly 48% of injectable therapy distribution because biologics require specialist monitoring and supervised administration.

Regional Outlook

The Psoriasis Treatment Market demonstrates strong regional variation, with North America holding approximately 39% market share due to advanced biologic adoption and high psoriasis diagnosis rates. Europe accounts for nearly 28% share supported by biosimilar expansion and reimbursement programs. Asia-Pacific contributes around 24% because of rising healthcare awareness and growing patient populations, while Middle East & Africa represent close to 9% with improving dermatology infrastructure and treatment accessibility.

Download FREE Sample to learn more about this report.

North America

North America dominates the Psoriasis Treatment Market with approximately 39% global share due to high diagnosis rates, strong healthcare infrastructure, and extensive biologic therapy adoption. The United States represents the largest regional contributor with more than 7.5 million diagnosed psoriasis patients, accounting for nearly 3.2% of the adult population. Around 58% of advanced psoriasis prescriptions in North America involve injectable biologics targeting IL-17, IL-23, and TNF-alpha inflammatory pathways. More than 60% of dermatology clinics integrated biologic monitoring programs by 2025 to support long-term therapy management.

Canada contributes significantly to regional demand, with psoriasis prevalence close to 2.5% of the population. Biosimilar penetration increased by approximately 30% across hospital procurement systems because healthcare providers focused on expanding affordability and treatment access. Nearly 48% of psoriasis-related hospital pharmacy dispensing in North America involves biologic injectables requiring clinical supervision. Teledermatology consultations increased by more than 43%, improving treatment accessibility in rural areas.

More than 40% of global psoriasis biologic clinical trials involve North American research institutions. Around 33% of psoriasis patients in the region experience psoriatic arthritis complications requiring long-term systemic treatment. Increasing obesity prevalence, autoimmune disease incidence, and advanced reimbursement systems continue supporting regional Psoriasis Treatment Market Growth and therapeutic innovation.

Europe

Europe accounts for approximately 28% share of the Psoriasis Treatment Market because of increasing biologic accessibility, rising biosimilar penetration, and favorable healthcare reimbursement systems. Germany, France, Italy, and the United Kingdom collectively contribute more than 65% of regional psoriasis treatment demand. Psoriasis prevalence across Europe ranges between 2% and 4% depending on national epidemiological patterns. More than 52% of severe psoriasis patients in Western Europe currently receive biologic or systemic therapies.

Biosimilar adoption increased significantly, with approximately 35% growth in TNF inhibitor biosimilar prescriptions during 2025. Hospital-based dermatology centers account for nearly 50% of advanced psoriasis therapy administration in the region. Around 44% of European dermatologists shifted prescribing patterns toward IL-23 inhibitors because of long-term disease control and lower relapse frequency.

Eastern European countries are experiencing improved psoriasis diagnosis rates because public awareness campaigns increased dermatology screening participation by nearly 27%. Approximately 38% of psoriasis patients across Europe also suffer from inflammatory comorbidities including psoriatic arthritis and metabolic syndrome. Injectable therapies dominate regional treatment demand with nearly 56% share because biologic therapies remain preferred for moderate-to-severe plaque psoriasis. Telemedicine integration expanded by over 32% across European dermatology clinics, improving follow-up monitoring and treatment adherence rates.

Asia-Pacific

Asia-Pacific represents approximately 24% share of the Psoriasis Treatment Market and continues expanding rapidly because of growing healthcare infrastructure and rising awareness regarding chronic inflammatory skin diseases. China, Japan, India, and South Korea collectively contribute more than 72% of regional psoriasis treatment demand. Psoriasis prevalence across Asia-Pacific ranges between 0.5% and 2.8%, with urban populations demonstrating higher diagnosis rates due to improved healthcare accessibility.

Biologic therapy adoption increased by approximately 32% during 2025 because hospitals expanded advanced dermatology treatment capabilities. Nearly 45% of Japanese dermatology hospitals integrated personalized biologic selection systems based on inflammatory biomarker profiles. In China, digital healthcare campaigns increased psoriasis screening participation by over 30%, improving early diagnosis and treatment initiation rates.

India remains one of the most significant growth markets because more than 10 million individuals are estimated to suffer from psoriasis-related conditions. Oral therapies contribute approximately 38% of advanced psoriasis treatment demand in Asia-Pacific because injectable biologics remain comparatively expensive for large patient populations. Biosimilar penetration increased by nearly 26% across urban healthcare systems because hospitals prioritized affordable biologic procurement. Around 34% of regional psoriasis clinical trials currently focus on TYK2 inhibitors and next-generation cytokine therapies, highlighting strong pharmaceutical innovation across Asia-Pacific healthcare markets.

Middle East & Africa

The Middle East & Africa region contributes approximately 9% share of the global Psoriasis Treatment Market due to improving healthcare infrastructure and expanding access to advanced dermatology services. Gulf countries including Saudi Arabia and the United Arab Emirates account for nearly 48% of regional advanced psoriasis treatment demand. Psoriasis prevalence in urban Middle Eastern populations ranges between 1% and 3%, while plaque psoriasis represents more than 80% of diagnosed cases.

Biologic therapy adoption increased by approximately 24% during 2025 because private hospitals expanded access to injectable IL-17 and TNF inhibitor therapies. Around 36% of dermatology clinics in Gulf countries integrated advanced biologic monitoring systems. Injectable therapies contribute nearly 54% of severe psoriasis treatment demand in the region, while oral therapies account for approximately 29%.

Africa remains an emerging market because specialist dermatology access remains limited in rural healthcare systems. However, awareness campaigns increased diagnosis rates by nearly 21% across major urban centers during 2024 and 2025. Biosimilar procurement volumes increased by approximately 18% in selected public hospitals because governments focused on improving affordability. More than 25% of psoriasis patients in the region continue relying on topical therapies due to uneven biologic accessibility. Expanding healthcare investment and private hospital development continue strengthening regional Psoriasis Treatment Market Opportunities.

Top Two Companies with Highest Market Share

• AbbVie holds approximately 12.5% share in the global Psoriasis Treatment Market because of its strong biologic therapy portfolio targeting TNF-alpha and IL-23 inflammatory pathways. Nearly 48% of AbbVie psoriasis prescriptions involve biologic therapies for moderate-to-severe plaque psoriasis.
• Johnson & Johnson accounts for approximately 10% market share due to extensive interleukin-targeting biologic therapies used in long-term plaque psoriasis and psoriatic arthritis management. Around 44% of its psoriasis treatment portfolio focuses on IL-23 and IL-12 pathway inhibitors.

Investment Analysis and Opportunities

Investment activity in the Psoriasis Treatment Market continues increasing because pharmaceutical companies are prioritizing cytokine-targeted biologics, oral TYK2 inhibitors, and biosimilar development. More than 54% of ongoing psoriasis clinical trials during 2025 focus on IL-23 inhibitors, IL-17 inhibitors, and oral immunomodulators. Pharmaceutical manufacturers expanded dermatology-focused research investments by approximately 31% between 2023 and 2025 due to rising demand for precision medicine and personalized biologic therapies.

Biologic manufacturing infrastructure investments increased by nearly 27% because injectable therapies contribute approximately 57% of advanced psoriasis treatment demand. Hospital procurement systems expanded biosimilar adoption by around 28%, creating strong opportunities for lower-cost biologic suppliers. Teledermatology platforms also attracted investment attention, with digital psoriasis consultations increasing by more than 40% globally.

Asia-Pacific remains a major investment destination because psoriasis diagnosis rates increased by approximately 30% in urban healthcare systems. Nearly 34% of emerging psoriasis clinical studies are currently conducted in Asian healthcare institutions. Oral therapies also present substantial opportunities, accounting for approximately 31% of treatment demand due to higher patient adherence rates. Strategic collaborations between pharmaceutical companies and dermatology clinics increased by approximately 22% during 2025 to support biologic monitoring and patient management programs.

New Product Development

New product development in the Psoriasis Treatment Market is primarily focused on next-generation biologics, oral TYK2 inhibitors, biosimilars, and advanced cytokine-targeting therapies. More than 18 late-stage clinical trials during 2025 evaluated therapies targeting IL-17, IL-23, and TYK2 inflammatory pathways. IL-17 inhibitors demonstrated PASI 75 response rates above 78% within 12 weeks, encouraging additional research into rapid skin-clearance biologics.

Oral TYK2 inhibitors emerged as a major innovation category because nearly 42% of psoriasis patients prefer non-injectable therapies. Several late-stage oral therapies demonstrated symptom reduction rates above 60% among moderate plaque psoriasis patients. Biosimilar development accelerated significantly, with approximately 28% increase in hospital procurement volumes for TNF inhibitor biosimilars during 2025.

Combination therapies integrating biologics with methotrexate gained importance because nearly 33% of severe psoriasis patients achieved improved disease control and lower relapse frequency through dual-treatment strategies. Around 46% of dermatology clinics integrated digital adherence monitoring systems to improve biologic therapy compliance. Pharmaceutical companies are also developing advanced auto-injectors and wearable biologic delivery devices to simplify patient administration. Pediatric psoriasis therapy innovation increased during 2025 because nearly 1% of children globally experience psoriasis-related inflammatory skin disorders.

Five Recent Developments (2023-2025)

• During 2025, IL-17 inhibitors achieved PASI 75 response rates above 78% within 12 weeks in severe plaque psoriasis clinical studies.
• In 2024, biosimilar procurement volumes for TNF inhibitors increased by approximately 28% across hospital systems due to expanded affordability initiatives.
• During 2025, more than 54% of psoriasis clinical trials focused on IL-23 pathways and next-generation cytokine-targeting therapies.
• In 2024, teledermatology consultations related to psoriasis management increased by over 40%, improving patient access to diagnosis and treatment recommendations.
• During 2023-2025, oral TYK2 inhibitors demonstrated symptom reduction rates above 60% in moderate plaque psoriasis studies, increasing physician adoption of oral systemic therapies.

Report Coverage of Psoriasis Treatment Market

The Psoriasis Treatment Market Report provides comprehensive analysis of therapeutic categories, treatment applications, regional demand patterns, competitive landscape, and emerging innovation trends across the global psoriasis treatment industry. The report evaluates biologics, oral systemic therapies, topical medications, biosimilars, and injectable treatment categories. More than 125 million psoriasis patients worldwide are included within the market evaluation framework, while approximately 30% develop psoriatic arthritis requiring advanced therapy.

The report covers segmentation analysis for TNF inhibitors, phosphodiesterase inhibitors, interleukin blockers, and other therapies. Injectable biologics account for approximately 57% of advanced psoriasis treatment demand, while oral therapies contribute nearly 31%. Regional analysis includes North America, Europe, Asia-Pacific, and Middle East & Africa, with North America holding approximately 39% market share.

The Psoriasis Treatment Market Research Report further analyzes more than 18 ongoing late-stage clinical trials focused on IL-17 inhibitors, IL-23 inhibitors, TYK2 inhibitors, and biosimilar therapies. Competitive profiling evaluates leading pharmaceutical manufacturers and biologic therapy portfolios. The report also examines teledermatology adoption rates exceeding 40%, biosimilar penetration growth of approximately 28%, and hospital pharmacy distribution trends accounting for nearly 48% of advanced psoriasis therapy dispensing worldwide.